Abstract
Background. Current lipid-lowering drugs often leave significant residual risk for adverse outcomes. Identification of previously approved drugs for new indications, drug repurposing, may provide a cost-effective alternative to de novo drug development. Objectives. We combined clinical, transcriptomic, computational, and experimental strategies to explore the lipid-lowering and plaque-stabilizing effects of the atypical antidepressant trazodone. Methods. A connectivity mapping strategy was used to match the rosuvastatin gene expression signature derived from a clinical trial of 85 patients to the expression patterns of 1,309 different small molecules. Validation was performed using HepG2 cells, molecular imaging of rabbit atherosclerotic lesions, and retrospective analysis of electronic medical records (EMR) from three large medical centers. Results. Trazodone significantly reduced cholesterol levels in the HepG2 human hepatocyte model, decreased atherosclerotic plaque burden in a rabbit model, and lowered low-density lipoprotein (LDL) cholesterol levels in patients. Conclusion. Our results indicate that trazodone may be a promising candidate for adjunctive lipid-lowering therapy. It may provide significant benefits to patients with hyperlipidemia, including lipid level reduction and formation of a more favorable atherosclerotic plaque morphology.
Introduction
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death globally. While statins are the gold standard for lowering "bad" LDL cholesterol, many patients still face a "residual risk" of heart attacks and strokes even with treatment. Newer drugs like PCSK9 inhibitors are effective but come with high price tags, limiting their accessibility. This paper explores drug repurposing—finding new uses for existing, FDA-approved medications—as a faster and more cost-effective alternative to de novo drug development. The authors specifically investigated whether trazodone, a common antidepressant, could lower lipids and stabilize the "necrotic cores" of arterial plaques, which are the volatile regions prone to rupturing and causing sudden cardiac events.
Methods
The study employed a "bench-to-bedside-and-back" approach involving four distinct phases:
- Computational Screening (Connectivity Mapping): Researchers used a gene-expression "signature" from patients in the YELLOW II clinical trial who showed plaque stabilization after high-intensity rosuvastatin therapy. They compared this signature against a database of 1,309 small molecules (CMap) to find drugs that induce similar genetic changes. Trazodone emerged as a top candidate.
- In Vitro Validation: Trazodone was tested on HepG2 (human liver) cells to determine if it directly inhibited cholesterol production, with atorvastatin serving as a control.
- Animal Modeling: In a rabbit model of atherosclerosis, subjects were treated with either atorvastatin or varying doses of trazodone. The team used advanced molecular imaging (SPECT/CT) with a radiolabeled peptide ($^{99m}$Tc-duramycin) to specifically bind to dying cells in the plaque's necrotic core.
- Retrospective Clinical Analysis: Electronic Medical Records (EMR) from Mount Sinai, Columbia, and UCSF were queried to see if patients prescribed trazodone for depression or insomnia experienced an incidental drop in LDL cholesterol.
Results
Overview of the study workflow and key findings across computational, in vitro, in vivo, and clinical datasets. Source, p. 1
The computational analysis revealed that trazodone's transcriptomic signature was more similar to rosuvastatin than many other statins were to each other, suggesting a shared mechanism of action. In cell culture, trazodone (50–100 μM) significantly reduced cholesterol levels in human hepatocytes, performing comparably to atorvastatin.
The rabbit studies demonstrated that trazodone didn't just shrink plaques; it changed their morphology. Molecular imaging showed that trazodone-treated rabbits had 42.7% to 50.8% lower plaque burden compared to untreated controls. Histopathology confirmed fewer inflammatory macrophages and smaller necrotic cores, indicating a more stable, fibrous structure.
In the retrospective human analysis, patients taking trazodone saw a statistically significant drop in LDL cholesterol. The effect was most notable at Mount Sinai, with a 3.73 mg/dL reduction (p=0.0004). While the numerical drop is modest compared to primary statin therapy, it provides crucial validation that the drug is active in humans.
Discussion and Conclusion
The authors identify the enzyme 7-dehydrocholesterol reductase (DHCR7) as the likely target for trazodone's lipid-lowering effects. Because trazodone is a psychiatric drug, its efficacy in HepG2 liver cells confirms a direct metabolic effect rather than a secondary result of improved sleep or mood.
While the study is limited by the retrospective nature of the EMR data and the known sedative side effects of trazodone, the findings are highly promising. Trazodone is positioned not as a replacement for statins, but as a potential adjunctive therapy—a well-understood, affordable option for patients who need additional lipid control or plaque stabilization. Prospective, randomized controlled trials (RCTs) are now necessary to determine if trazodone can effectively reduce the incidence of heart attacks in human populations.
Summary updated